Positive sentinel lymph node in a patient with clinical stage I vaginal cancer by Lauren Montemorano, Monica Hagan Vetter, Michael Blumenfeld, David M. O'Malley

Get full text

Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series by Corinne A. Calo, Monica D. Levine, Morgan D. Brown, David M. O'Malley, Floor J. Backes

Get full text

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine by Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O'Malley, Ursula Matulonis, Gottfried E. Konecny

Get full text

Overcoming the challenges of drug development in platinum-resistant ovarian cancer by Ramez N. Eskander, Kathleen N. Moore, Bradley J. Monk, Thomas J. Herzog, Christina M. Annunziata, David M. O’Malley, Robert L. Coleman

Get full text

Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II? by Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, Floor J. Backes

Get full text

Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer by Rachael N. Piver, Vincent M. Wagner, Monica D. Levine, Floor J. Backes, Laura J. Chambers, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Christa I. Nagel, David M. O'Malley, Kristin L. Bixel

Get full text

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA tr... by Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin